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osting by EAbstract Orbital retinoblastoma is a catastrophic event traditionally carrying a dismal prognosis.
Although its incidence is less in the developed countries it continues to be one of the major diagnosis
at presentation in the developing world. Orbital retinoblastoma encompasses a wide range of dis-
tinct clinical entities with varying tumor load. There are no standard treatment protocols as of
now but the current preferred management is multimodal with a combination of initial high-dose
chemotherapy, surgery, external beam radiotherapy and prolonged chemotherapy for twelve cycles.
In spite of progress on all fronts including surgical, medical, diagnostic, genetic and rehabilitative
with improving survival rates, however, lack of access to medical facilities, lack of education about
the need for early medical attention and cultural resistance to enucleation continue to contribute to
an epidemic of extra ocular disease at diagnosis in the developing world. This review introduces the
various terminologies used in the spectrum of orbital retinoblastoma, discusses in details the clinical
aspects and management protocols, current status and the future directions.
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Retinoblastoma is the most common intraocular malignancy
in children, with a reported incidence ranging from 1 in
15,000 to 1 in 18,000 live births (Bishop and Madsen, 1975).
It is bilateral in about 25–35% of cases (Shields, 1992). The
average age at diagnosis is 18 months, unilateral cases being
diagnosed at around 24 months and bilateral cases before
12 months (Shields, 1992). Retinoblastoma was associated with
near certain death just over a century ago. Early tumor recog-
nition aided by indirect ophthalmoscopy and reﬁned enucle-
ation technique contributed to an improved survival from
5% in 1896 to 81% in 1967. Advances in external beam radio-
therapy in the 1960s and 1970s, resulted in further substantial
eye salvage (Shields, 1992).
The recent advances like identiﬁcation of genetic mutations,
replacement of external beam radiotherapy by chemoreduction
as the primary management modality, use of chemoreduction
to minimize the size of regression scar with consequent optimi-
zation of visual potential, identiﬁcation of histopathologic high
risk features following enucleation and provision of adjuvant
therapy to reduce the incidence of systemic metastasis, protocol
based management of retinoblastoma with accidental perfora-
tion or intraocular surgery and aggressive multimodal therapy
in the management of orbital retinoblastoma have contributed
to improved outcomes in terms of better survival, improved eye
salvage and potential for optimal visual recovery.
2. Present status
In neglected or untreated cases retinoblastoma can demon-
strate extra ocular spread primarily through the optic nerve
(Magramm et al., 1989) and also through the sclera (Rootman
et al., 1978). Though it is a rare clinical presentation in devel-oped countries ranging from 6.3% to 7.6% (Grabowski and
Abramson, 1987; Ellsworth, 1974), it is not an unusual feature
in developing and under developed world. Leal-Leal et al.
(2004) reported an incidence of 18% in a large multi-center
study from Mexico. Kao et al. (2002) from Taiwan reported
the incidence of orbital retinoblastoma to be 36% in a large
study. The incidence is even higher around 40% from Nepal
where Badhu et al. (2005) reported proptosis to be the most
common presenting feature of retinoblastoma.
Orbital retinoblastoma is one of the major contributors to
mortality and carries a poor prognosis for life. (Stannard
et al., 1979; Hungerford, 1993; Finger et al., 2002; Abramson
et al., 2003; Schvartzman et al., 1996). The presence of
orbital invasion is associated with 10 to 27 time’s higher risk
of metastasis when compared to cases without orbital exten-
sion (Singh et al., 2000; Kopelman et al., 1987; Khelfaoui
et al., 1996).
The 5 year survival rates of orbital retinoblastoma have been
reported to be 88%fromUnitedKingdom (Sanders et al., 1988),
91% from Japan (Anonymous, 1992) and 93% from United
States (Abramson et al., 1994; Young et al., 1999). However,
the mortality in developing countries is still high owing to late
presentations compounded by socio-economic factors with the
mortality reported as high as 50–90% (Badhu et al., 2005;
Schvartzman et al., 1996; Ajaiyeoba et al., 1993; Chantada
et al., 1999; Kodilinye, 1967).3. Classiﬁcations
Orbital retinoblastomas have been variously classiﬁed. Child-
rens Cancer Group (CCG) classiﬁcation criteria (Wolff et al.,
1978) (Table 1) and classiﬁcation based on the clinicopatholog-
ical presentations (Honavar, 2007) (Table 2) are used.
Table 1 Childrens cancer group classiﬁcation of orbital
retinoblastoma.
Class Feature
Class I Microscopic involvement of scleral emissaries
Class II Microscopic involvement of cut end of optic nerve
Class III Orbital disease in the biopsy
Class IV CNS disease with brain mass or CSF with
positive tumor cells
Class V Blood borne metastasis to bone marrow,
bone or lymphatic metastasis to lymph nodes
Table 2 Clinicopathological Classiﬁcation of Orbital
Retinoblastoma.
1 Primary orbital retinoblastoma
2 Secondary orbital retinoblastoma
3 Accidental orbital retinoblastoma
4 Overt orbital retinoblastoma
5 Microscopic orbital retinoblastoma
Figure 1 (a and b). Bilateral advance retinoblastoma. Left eye
gross proptosis and right eye anterior segment seeding can be
appreciated. (a) CT Scan axial cuts of the same patient conﬁrmed
orbital mass and gross optic nerve extension (b).
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4.1. Presenting Age
It is well known that orbital retinoblastomas manifest com-
monly due to late presentations. The average age at diagnosis
is 18 months (Shields, 1992). In contrast to this Menon et al.
(2000) reported the average age at diagnosis to be 30 months
for orbital retinoblastoma whereas Doz et al. (1995) and Anto-
neli et al. (2003) reported it as 38 and 32.9 months respectively.
4.2. Most common presenting feature
The most common presenting sign or symptom was leukokoria
in the Antoneli et al. (2003) (68%) in comparison to Menon et
al. (2000) where it was reported to be 72%. But in the Menon
et al. (2000) series proptosis was the most common presenting
sign (83%). The rate of proptosis as the most common present-
ing sign was 75.9% versus 24.1%, in patients with unilateral
and bilateral disease.
4.3. Primary orbital retinoblastoma
This refers to a clinically or radiologically detected orbital
extension of an intraocular retinoblastoma at the initial pre-
sentation, with or without proptosis or a fungating mass. Si-
lent proptosis with manifest intraocular tumor is the usual
presentation (Fig 1a and b). Proptosis with inﬂammation gen-
erally indicates reactive sterile orbital cellulitis secondary to
intraocular tumor necrosis. Palpable orbital mass (Fig. 2) , eye-
lid swelling or an exuberant fungating orbital mass (Fig. 3) are
other manifestations. (Honavar, 2007).
4.4. Secondary orbital retinoblastoma
This refers to orbital recurrence following an uncomplicated
enucleation for intraocular retinoblastoma. Orbital recurrence
may present between weeks to years after the primary surgery.
Unexplained displacement, bulging or extrusion of a previ-
ously well ﬁtting conformer or prosthesis is a characteristicﬁnding. Secondary orbital retinoblastomas may also present
as a conjunctival nodule (Honavar, 2007).
Orbital recurrence of retinoblastoma after enucleation
usually carries poor prognosis with reported rates of mortality
being as high as 94–100% (Hungerford et al., 1987; Reese,
1963). Distant relapse was found to be the commonest cause
of mortality (Reese, 1963).
4.5. Accidental orbital retinoblastoma
This refers to inadvertent perforation, ﬁne needle aspiration
biopsy or intraocular surgery in an eye with unsuspected intra-
ocular retinoblastoma (Honavar, 2007).
4.6. Overt Orbital Retinoblastoma
This refers to previously unrecognized extrascleral or optic
nerve extension discovered during enucleation. A pale pink
episcleral nodule or an enlarged and inelastic optic nerve are
indicators of overt orbital retinoblastoma that needs to be rec-
ognized during enucleation ( Honavar, 2007). The prognosis
can be dismal if these cases are not managed carefully.
4.7. Microscopic Orbital Retinoblastoma
This refers to retinoblastomas with full thickness scleral inﬁl-
tration, extrascleral extension or invasion of the optic nerve
Figure 4 Histopathology specimen of an enucleated eye dem-
onstrating extra scleral extension of the tumor.
Figure 2 Primary orbital retinoblastoma. The right eye shows
proptosis with extra scleral extension in the form of nodular
masses.
Figure 3 Fungating orbital retinoblastoma.
162 M.J. Ali et al.on histopathologic evaluation of an enucleated eye for intraoc-
ular retinoblastoma (Fig. 4). There may not be any clinically
evident orbital extension of retinoblastoma (Honavar, 2007).
These high risk histopathologic features have a strikingly high-er incidence in developing countries as compared to the pub-
lished data from the developed countries (Magramm et al.,
1989; Kopelman et al., 1987; Khelfaoui et al., 1996; Messmer
et al., 1989; Shields et al., 1994) as demonstrated by Vemuganti
et al. (2000). In this series 46% of the 76 eyes enucleated for
advance retinoblastoma in India had optic nerve invasion at
or beyond lamina cribrosa and 7% had scleral inﬁltration or
extrascleral extension. This could also partly contribute to
the high incidence of orbital retinoblastoma in developing
countries.
5. Investigations
A careful and detailed evaluation of the patient is mandatory.
Apart from the routine clinical work up, regional lymph nodes
need to be palpated and a ﬁne needle aspiration biopsy should
be done if found to be involved. Imaging modality of choice is
MRI of orbits and brain. Alternatively a CT Scan can also be
performed to conﬁrm the presence of orbital retinoblastoma.(
Fig. 5a and b) A metastasis work up involves bone marrow
biopsy and cerebrospinal ﬂuid cytology. Whole body bone
scans using technetium-99 as shown by Kiratli et al. (1998)
and Flourine-18 ﬂourodeoxyglucose positron emission tomog-
raphy (PET CT) as demonstrated by Moll et al. (2004) may
pick up early metastasis. Biopsy can be done in those cases
where the primary diagnosis or histopathology is unavailable.
6. Treatment
6.1. Primary orbital retinoblastoma
There are no proven deﬁnitive therapy or management proto-
cols for orbital retinoblastoma. They continue to remain a
challenging disease to treat because of its complex nature
and usually various combination therapies are needed to
achieve reasonable results. White (1991) has discussed the
use of chemotherapeutic agents including cyclophosphamide,
teniposide, cisplatin, vincristine, doxorubicin in conjunction
with external beam radiotherapy. Menon et al. (2000) and
Doz et al. (1995) have shown encouraging results with the
use of etoposide in the management protocols. Acquaviva
Figure 5 (a and b). CT Scan axial cuts show gross left optic
nerve thickening of the tumor measured radiologically (a) CT Scan
axial cuts show gross left optic nerve extension along with
intracranial extension (b).
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radiotherapy. On the other hand (Antoneli et al., 2003) showed
no beneﬁt from aggressive chemotherapy alone. Goble et al.
(1990) showed good long term survival with multimodal
therapy.
6.1.1. Why do we need multimodal therapy ?
(a) Systemic chemotherapy alone is unlikely to eradicate
residual orbital disease (Antoneli et al., 2003; Doz
et al., 1994).
(b) Orbital exenteration alone is unlikely to achieve surgical
clearance (Hungerford et al., 1987; Reese, 1963).
(c) External beam radiotherapy is unlikely to prevent sys-
temic metastasis (Amendola et al., 1990; Scott et al.,
1999).
(d) Histopathologic evidence of viable tumor cells even in
phthisical eyes following neoadjuvant chemotherapy
(Ali et al., 2009).
Based on the current evidence as mentioned above Honavar
and Singh (2005) developed a treatment protocol comprising
of initial triple drug high-dose chemotherapy (3–6 cycles) fol-
lowed by appropriate surgery, orbital radiotherapy and anadditional 12 cycle standard dose chemotherapy. Detailed pro-
tocol is listed in Table 3.
In this series six cases of orbital retinoblastoma without
intracranial extension and systemic metastasis underwent the
protocol as described above and the authors reported dramatic
resolution of orbital involvement and a mean event-free sur-
vival of 36 months. Most of the eyes following chemotherapy
become phthisical (Fig. 6a and b). The authors agreed that
their encouraging protocol needs validation and further studies
are needed to know whether fewer cycles are as equally effec-
tive since there are concerns of the long term effects of high-
dose chemotherapy.
6.2. Secondary orbital retinoblastoma
Hungerford et al. (1987) and Reese (1963) have reported dismal
results and poor prognosis for cases of orbital recurrences.
None of the 25 cases reported by Reese et al. survived. Most
of the deaths occur within two years. The point to be taken into
account in these series was the lack of multimodal approach. In
contrast Goble et al. (1990) demonstrated long term survival
with local surgical excision, orbital radiotherapy and systemic
chemotherapy. Antoneli et al. (2003) reported encouraging re-
sults from multimodal approaches but were not supportive of
aggressive chemotherapy. Based on the increasing literature
support for a multimodal therapy (Honavar and Singh, 2005)
proposed a protocol (Table 3) that is currently under investiga-
tion for the management of secondary orbital retinoblastoma
with very encouraging early results. However long term results
of all the current multimodal protocols need to be reviewed be-
fore deﬁnite protocols can be formulated in future.
6.3. Accidental orbital retinoblastoma
Eyes with retinoblastoma undergoing enucleation deserves
special considerations (Honavar, 2007):
(a) All efforts should be taken to prevent accidental
perforation.
(b) It is preferable to avoid applying traction sutures at the
insertion of extra ocular muscles to avoid perforation.
(c) Hemostats applied to muscle stumps provide adequate
traction.
(d) Retinoblastoma with sterile orbital cellulitis should be
adequately treated to reduce the inﬂammation before
enucleation.
Eyes with retinoblastoma which underwent inadvertent
intraocular surgery should immediately undergo an extended
enucleation that additionally includes the conjunctiva overlying
the entry points or over the ports with a 4 mmmargin all around
(Shields et al., 2000). In cases where prompt enucleation is not
possible all such entry points or ports should be subjected to tri-
ple freeze–thaw cryotherapy followed by enucleation as appro-
priate. All such eyeballs merit special histopathologic analysis
for high risk features and speciﬁc analysis of the entry wounds
for the presence of tumor cells. Metastasis work up in the form
of bone marrow biopsy and cerebrospinal ﬂuid analysis for the
presence of tumor cells is mandatory. Following enucleation,
it is recommended to subject the patients to orbital external
beam radiotherapy and 12 cycles of high-dose chemotherapy
(Shields et al., 2000).
Table 3 Suggested protocol for primary orbital retinoblastoma.
Baseline investigations
CT Scan or Magnetic resonance imaging
Bone marrow biopsy
Cerebrospinal ﬂuid cytology
Treatment
Initial Chemotherapy –High dose triple-drug chemotherapy for
3–6 cycles every three weeks.
Surgery –Enucleation
Assessment of orbital tumor by imaging
after completion of third cycle. If resolved
than proceed with enucleation. If
unresolved give additional 3 cycles of
chemotherapy.
Assessment of orbital tumor after
completion of 6 cycles. If resolved proceed
with enucleation and if not proceed with
exenteration.
Radiotherapy –45–50 Gy in fractionated doses to the
orbit.(External beam)
Subsequent chemotherapy –Continuation of high-dose chemotherapy
for 12 cycles
Follow-up investigations
Imaging at 12, 18, 24 and 36 months. Bone marrow biopsy
and cerebrospinal ﬂuid cytology at 6, 12, 18, 24 and 36 months.
High-dose chemotherapy (mg/kg body weight)
Vincristine –Day 1–0.025 mg/kg
Etoposide –Day 1–12 mg/kg
–Day 2–12 mg/kg
Carboplatin –Day 1–28 mg/kg
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Extra ocular extension suspected during surgery deserves spe-
cial considerations.
(a) If an extra-scleral lesion is visible, it should be com-
pletely excised along with the overlying tenon’s capsule
during enucleation (Honavar and Singh, 2005).
(b) The surgeon should aim at an optic nerve length of
15 mm. In case due to unforeseen circumstances the
length of the optic nerve obtained is less than 10 mms
when it is suspected to be involved due to increased
thickness or inelasticity, Honavar (2007) preferred to
explore the orbit and attempt an additional optic nerve
length during the same sitting.
(c) Biointegrated implants should be avoided in suspected
cases of orbital retinoblastoma as there is possibility of
implant exposure due to subsequent external beam
radiotherapy.
All cases of overt orbital retinoblastoma undergo metasta-
sis work up in the form of bone marrow biopsy and cerebrospi-
nal ﬂuid analysis for the presence of tumor cells. Following
enucleation, it is recommended to subject the patients to orbi-
tal external beam radiotherapy and 12 cycles of high-dose che-
motherapy (Shields et al., 2000).
Chantada et al. (2003) in an exclusive study of overt
orbital retinoblastoma using a multimodal approach has
shown 5 year event-free survival rates to be 84% in a group
of 15 patients.6.5. Microscopic orbital retinoblastoma
Several studies have now identiﬁed high risk factors for extra
ocular recurrences to be post-laminar optic nerve involvement,
invasion of optic nerve transection, massive choroidal inva-
sion, scleral inﬁltration and even anterior chamber involve-
ment (Magramm et al., 1989; Stannard et al., 1979;
Schvartzman et al., 1996; Khelfaoui et al., 1996; Uusitalo
et al., 2001; Honavar et al., 2002). The patients where the tu-
mor involved the cut end of optic nerve, scleral or extrascleral
involvement are recommended to undergo external beam
radiotherapy followed by 12 cycles of high-dose chemother-
apy. (Honavar and Singh, 2005).
7. Glimpse of the future and its challenges
When reviewing the literature one fact that stands out clearly is
the increasing survival of patients with orbital retinoblastoma.
Progress has been made and is continuing on all fronts includ-
ing surgical, medical, diagnostic, genetic and rehabilitative
(Shields and Shields, 2010; Bakhshi et al., 2010).
Multimodal therapies for advanced retinoblastoma are
picking up pace and support from all spheres as amply eluci-
dated in this review. Histopathologic evaluations of eyes fol-
lowing neoadjuvant chemotherapy for orbital retinoblastoma
have further vouched for multimodal approaches (Ali et al.,
2009). The introduction of stem cell rescue along with high-
dose chemotherapy has added another dimension to the treat-
ment of orbital retinoblastoma (Kremens et al., 2003; Lee
et al., 2008). The Children’s Oncology Group trials (COG
Figure 6 (a and b). Bilateral phthisical eyes following chemo-
therapy for advance retinoblastoma (a). CT Scans with saggital
reconstruction of the same patient (b).
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dardize the treatment protocols worldwide. Their well de-
signed COG ARET 0321 trial of intensive multimodal
therapy for extra ocular retinoblastoma will probably lay to
rest most of the confusion revolving around management
protocols.
Advances in external beam radiotherapy for retinoblastoma
with more precise control of the beam through better collima-
tion and tighter isodose curves strongly argue its continuing
supportive role in the management. The modern approaches
that are being investigated include stereo tactic conformal
radiotherapy using a micromultileaf collimator, proton ther-
apy using a ﬁxed horizontal beam and tantalum localization
or a rotating gantry with spot scanning (Munier et al., 2008).
Better survival has led to increasing research in newer implants
with focus on orbital development and hence better cosmesis.
On the diagnostic front exploring the fetal eye is a new
frontier. Fetal Magnetic resonance imaging (MRI) and fetal
three-dimensional ultrasound are being increasingly explored
for prenatal diagnosis. The only two cases reported of in utero
diagnosis using fetal ultrasound had massive extra ocular
extension (Maat-Kevit et al., 1993; Salim and Wiknjosastro,
1998). Whole body bone scans using technetium-99 as shown
by Kiratli et al. (1998) and Flourine-18 ﬂourodeoxyglucose
positron emission tomography (PET CT) as demonstrated by
Moll et al. (2004) reﬂect a glimpse of what possibly lies in store
for early detection of metastasis.On the genetic front there has not been a great progress in-
spite of the fact that RB1 was the ﬁrst human cancer gene to be
cloned. Development of an automated, inexpensive screening
examination for RB1 mutations has been a long term need.
However recently Parsam et al. (2009) from the authors group
have developed and published a combinatorial and less expen-
sive approach for the detection of RB1 mutations which is
likely to have applications as a screening tool. Ali et al.
(2010) have for the ﬁrst time explored the possible correlations
between different types of mutations on the RB1 gene and clin-
ical presentations. It is interesting to note that large deletions
were found to correlate with extra ocular extension and metas-
tasis at presentation. Further efforts are needed to make it a
routine part of patient care.
On the social front awareness through education and out-
reach to the community has helped to prevent delayed presen-
tations and an early referral. Impact of educational
programmes in certain developing nations of Central America
where it was linked with the vaccination programmes is contin-
uing to yield encouraging results with the rate of orbital retino-
blastoma diagnosis reducing by almost half in the post-
campaign period (Leander et al., 2007; Wilimas et al., 2009).
Similar programmes could be cloned to developing countries
in Africa and Southern Asia speciﬁcally targeting the educa-
tion of general population and primary care providers.
Lastly other areas being investigated include pharmacologic
enhancement of radiotherapy, use of tumor cell targeting tech-
niques, differentiating agents, immunotherapy and employing
metastasis suppressor genes to prevent metastasis. (White,
1991; Kauffman et al., 2003).
8. Conclusions
Orbital retinoblastoma still stands as a tall challenge requiring
multi-modal and multi-disciplinary approach. The Childrens
Oncology Group trial for extra ocular retinoblastoma is likely
to formulate an effective and standardized management proto-
col in the near future. Although the survival has increased over
the last few years, lack of access tomedical facilities, lack of edu-
cation about the need for early medical attention and cultural
resistance to enucleation continue to contribute to an epidemic
of extra ocular disease at diagnosis in the developing world. The
goals for the future need to be well designed, implemented and
spread over medical, socio-economic and research frontiers.References
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